{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T02:02:35Z","timestamp":1793757755760,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC8048424"],"award-info":[{"award-number":["RC8048424"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["PE00000007, INF-ACT"],"award-info":[{"award-number":["PE00000007, INF-ACT"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89312-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T16:32:20Z","timestamp":1743784340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Human type I interferons protect Vero E6 and ARPE-19 cells against West Nile virus and are neutralized by pathogenic autoantibodies"],"prefix":"10.1038","volume":"15","author":[{"given":"Alessandro","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cassaniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rovida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Lilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Croce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Trespidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ghirardello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Laurent","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Borghesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Baldanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"89312_CR1","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature09907","volume":"472","author":"JW Schoggins","year":"2011","unstructured":"Schoggins, J. W. et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481\u2013485. https:\/\/doi.org\/10.1038\/nature09907 (2011).","journal-title":"Nature"},{"key":"89312_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrmicro2950","volume":"11","author":"MS Suthar","year":"2013","unstructured":"Suthar, M. S., Diamond, M. S. & Gale, M. Jr West Nile virus infection and immunity. Nat. Rev. Microbiol. 11, 115\u2013128. https:\/\/doi.org\/10.1038\/nrmicro2950 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"89312_CR3","doi-asserted-by":"publisher","first-page":"13350","DOI":"10.1128\/JVI.79.21.13350-13361.2005","volume":"79","author":"MA Samuel","year":"2005","unstructured":"Samuel, M. A. & Diamond, M. S. Alpha\/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79, 13350\u201313361. https:\/\/doi.org\/10.1128\/JVI.79.21.13350-13361.2005 (2005).","journal-title":"J. Virol."},{"key":"89312_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10875-020-00930-3","volume":"41","author":"C Oleaga-Quintas","year":"2021","unstructured":"Oleaga-Quintas, C. et al. Inherited GATA2 deficiency is dominant by haploinsufficiency and displays incomplete clinical penetrance. J. Clin. Immunol. 41, 639\u2013657. https:\/\/doi.org\/10.1007\/s10875-020-00930-3 (2021).","journal-title":"J. Clin. Immunol."},{"key":"89312_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10875-018-0512-0","volume":"38","author":"I Sologuren","year":"2018","unstructured":"Sologuren, I. et al. Lethal influenza in two related adults with inherited GATA2 deficiency. J. Clin. Immunol. 38, 513\u2013526. https:\/\/doi.org\/10.1007\/s10875-018-0512-0 (2018).","journal-title":"J. Clin. Immunol."},{"key":"89312_CR6","doi-asserted-by":"publisher","first-page":"e20240637","DOI":"10.1084\/jem.20240637","volume":"221","author":"A Gervais","year":"2024","unstructured":"Gervais, A. et al. Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in \u223c10% of patients. J. Exp. Med. 221, e20240637. https:\/\/doi.org\/10.1084\/jem.20240637 (2024).","journal-title":"J. Exp. Med."},{"key":"89312_CR7","doi-asserted-by":"publisher","first-page":"eabd4585","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard, P. et al. Autoanti- bodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585. https:\/\/doi.org\/10.1126\/science.abd4585 (2020).","journal-title":"Science"},{"key":"89312_CR8","doi-asserted-by":"publisher","first-page":"e13116","DOI":"10.1111\/irv.13116","volume":"17","author":"F Alotaibi","year":"2023","unstructured":"Alotaibi, F. et al. Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir Viruses. 17, e13116. https:\/\/doi.org\/10.1111\/irv.13116 (2023).","journal-title":"Influenza Other Respir Viruses"},{"key":"89312_CR9","doi-asserted-by":"publisher","first-page":"e2250164","DOI":"10.1002\/eji.202250164","volume":"53","author":"BG Hale","year":"2023","unstructured":"Hale, B. G. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. Eur. J. Immunol. 53, e2250164. https:\/\/doi.org\/10.1002\/eji.202250164 (2023).","journal-title":"Eur. J. Immunol."},{"key":"89312_CR10","doi-asserted-by":"publisher","first-page":"e20211387","DOI":"10.1084\/jem.20211387","volume":"219","author":"A Puel","year":"2022","unstructured":"Puel, A., Bastard, P., Bustamante, J. & Casanova, J. L. Human auto- antibodies underlying infectious diseases. J. Exp. Med. 219, e20211387. https:\/\/doi.org\/10.1084\/jem.20211387 (2022).","journal-title":"J. Exp. Med."},{"key":"89312_CR11","doi-asserted-by":"publisher","first-page":"e20202486","DOI":"10.1084\/jem.20202486","volume":"218","author":"P Bastard","year":"2021","unstructured":"Bastard, P. et al. Auto- antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486. https:\/\/doi.org\/10.1084\/jem.20202486 (2021).","journal-title":"J. Exp. Med."},{"issue":"9","key":"89312_CR12","doi-asserted-by":"publisher","first-page":"e20230661","DOI":"10.1084\/jem.20230661","volume":"220","author":"A Gervais","year":"2023","unstructured":"Gervais, A. et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in \u223c40% of patients. J. Exp. Med. 220 (9), e20230661. https:\/\/doi.org\/10.1084\/jem.20230661 (2023).","journal-title":"J. Exp. Med."},{"key":"89312_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140\u2013145. https:\/\/doi.org\/10.1038\/s41586-020-2918-0 (2021).","journal-title":"Nature"},{"key":"89312_CR14","doi-asserted-by":"publisher","unstructured":"Manry, J. et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl. Acad. Sci. USA. 119 (e2200413119). https:\/\/doi.org\/10.1073\/pnas.2200413119 (2022).","DOI":"10.1073\/pnas.2200413119"},{"issue":"3","key":"89312_CR15","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1001\/jama.2013.8042","volume":"310","author":"LR Petersen","year":"2013","unstructured":"Petersen, L. R., Brault, A. C. & Nasci, R. S. West Nile virus: Review of the literature. JAMA 310 (3), 308\u2013315. https:\/\/doi.org\/10.1001\/jama.2013.8042 (2013).","journal-title":"JAMA"},{"issue":"4","key":"89312_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jama.290.4.524","volume":"290","author":"LR Petersen","year":"2003","unstructured":"Petersen, L. R., Marfin, A. A. & Gubler, D. J. West Nile virus. JAMA 290 (4), 524\u2013528. https:\/\/doi.org\/10.1001\/jama.290.4.524 (2003).","journal-title":"JAMA"},{"key":"89312_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.saep.2004.01.002","volume":"13","author":"DN Phalen","year":"2004","unstructured":"Phalen, D. N. & Dahlhausen, B. West Nile virus. Semin. Avian exot. Pet. Med. 13, 67\u201378. https:\/\/doi.org\/10.1053\/j.saep.2004.01.002 (2004).","journal-title":"Semin. Avian exot. Pet. Med."},{"issue":"4","key":"89312_CR18","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00705-004-0463-z","volume":"150","author":"KM van der Meulen","year":"2005","unstructured":"van der Meulen, K. M., Pensaert, M. B. & Nauwynck, H. J. West Nile virus in the vertebrate world. Arch. Virol. 150 (4), 637\u2013657. https:\/\/doi.org\/10.1007\/s00705-004-0463-z (2005).","journal-title":"Arch. Virol."},{"key":"89312_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-3-642-59403-8_15","volume":"267","author":"M Malkinson","year":"2002","unstructured":"Malkinson, M. & Banet, C. The role of birds in the ecology of West Nile virus in Europe and Africa. Curr. Top. Microbiol. Immunol. 267, 309\u2013322. https:\/\/doi.org\/10.1007\/978-3-642-59403-8_15 (2002).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"89312_CR20","unstructured":"European Centre for Disease Prevention and Control. Factsheet about West Nile virus infection. (2023). Available at https:\/\/www.ecdc.europa.eu\/en\/ west-nile-fever\/facts (Accessed Feb 20, 2024)."},{"key":"89312_CR21","unstructured":"Centers for Disease Control and Prevention. West Nile virus. (2023). Available at https:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html (Accessed Feb 20, 2024)."},{"issue":"6","key":"89312_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/v3060811","volume":"3","author":"SM Lim","year":"2011","unstructured":"Lim, S. M., Koraka, P., Osterhaus, A. D. & Martina, B. E. West Nile virus: Immunity and pathogenesis. Viruses 3 (6), 811\u2013828. https:\/\/doi.org\/10.3390\/v3060811 (2011).","journal-title":"Viruses"},{"issue":"4","key":"89312_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s11908-011-0193-9","volume":"13","author":"RL Debiasi","year":"2011","unstructured":"Debiasi, R. L. West Nile virus neuroinvasive disease. Curr. Infect. Dis. Rep. 13 (4), 350\u2013359. https:\/\/doi.org\/10.1007\/s11908-011-0193-9 (2011).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"89312_CR24","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1038\/s41467-023-41600-3","volume":"14","author":"B Shrestha","year":"2023","unstructured":"Shrestha, B., Huynh, N. & Diamond, M. S. Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease. Nat. Commun. 14, 5973. https:\/\/doi.org\/10.1038\/s41467-023-41600-3 (2023).","journal-title":"Nat. Commun."},{"key":"89312_CR25","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","volume":"80","author":"N Ank","year":"2006","unstructured":"Ank, N. et al. Lambda Interferon (IFN-\u03bb), a type III IFN, is Induced by viruses and IFNs and displays potent antiviral activity against select virus infections. Vivo J. Virol. 80, 4501\u20134509. https:\/\/doi.org\/10.1128\/JVI.80.9.4501-4509.2006 (2006).","journal-title":"Vivo J. Virol."},{"key":"89312_CR26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3389\/fimmu.2019.01182","volume":"10","author":"Y Ning","year":"2019","unstructured":"Ning, Y. et al. Interferon-\u03b3-directed inhibition of a novel high-pathogenic phlebovirus and viral antagonism of the antiviral signaling by targeting STAT1. Front. Immunol. 10, 1182. https:\/\/doi.org\/10.3389\/fimmu.2019.01182 (2019).","journal-title":"Front. Immunol."},{"key":"89312_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/v12020157","volume":"12","author":"E Percivalle","year":"2020","unstructured":"Percivalle, E. et al. West Nile or Usutu virus? A three-year follow-up of humoral and cellular response in a group of asymptomatic blood donors. Viruses 12, 157. https:\/\/doi.org\/10.3390\/v12020157 (2020).","journal-title":"Viruses"},{"key":"89312_CR28","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/imr.12001","volume":"250","author":"J Piehler","year":"2012","unstructured":"Piehler, J., Thomas, C., Garcia, K. & Schreiber, G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250, 317\u2013334. https:\/\/doi.org\/10.1111\/imr.12001 (2012).","journal-title":"Immunol. Rev."},{"key":"89312_CR29","doi-asserted-by":"publisher","unstructured":"Casanova, J., MacMicking, J. & Nathan, C. F. Interferon-\u03b3 and infectious diseases: Lessons and prospects. Science 384 https:\/\/doi.org\/10.1126\/science.adl2016 (2024).","DOI":"10.1126\/science.adl2016"},{"key":"89312_CR30","doi-asserted-by":"publisher","unstructured":"Vanker, M. et al. Autoantibodies neutralizing type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia. J. Interferon Cytokine Res. 43, 379\u2013393. https:\/\/doi.org\/10.1089\/jir.2023.0003 (2023).","DOI":"10.1089\/jir.2023.0003"},{"key":"89312_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/jci.2023.0015","volume":"44","author":"M Menon","year":"2023","unstructured":"Menon, M. et al. A sensitive assay for measuring whole-blood responses to type I IFNs presents a diagnostic method for detecting inborn errors in type I interferon (IFN) immunity and autoantibodies neutralizing IFNs. J. Clin. Immunol. 44, 215\u2013229. https:\/\/doi.org\/10.1089\/jci.2023.0015 (2023).","journal-title":"J. Clin. Immunol."},{"key":"89312_CR32","doi-asserted-by":"publisher","first-page":"e20240942","DOI":"10.1084\/jem.20240942","volume":"221","author":"A Gervais","year":"2024","unstructured":"Gervais, A. et al. Auto-abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease. J. Exp. Med. 221, e20240942. https:\/\/doi.org\/10.1084\/jem.20240942 (2024).","journal-title":"J. Exp. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89312-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89312-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:49:00Z","timestamp":1744285740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89312-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89312"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89312-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.-L. Casanova reported a patent to PCT\/US2021\/042741 pending. No other disclosures were reported from other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11271"}}